Tiefenbacher Group and OnDosis have announced the signing of a co-development agreement for multiple products in the upcoming years.

The agreement covers future potential collaboration of products within five disease areas, where individualized dosing, improved patient engagement and patient safety are important to improve outcomes, they state.

The first project within ADHD is already initiated

The first co-development project is already initiated within ADHD and targeting the US market. Through the collaboration, OnDosis will benefit from a partner with leading competence in pharmaceutical development, supply chain and B2B commercialization, whilst Tiefenbacher Group gets access to an innovative product concept with game-changing potential in the new era of individualization of treatments and digitalization in healthcare, the companies’ state.

“We are very excited by this great opportunity. The collaboration between Tiefenbacher Group and OnDosis builds on a very strong logic, where the joint capabilities of our companies and commitment of our teams will enable acceleration towards of our mission to bring truly game changing therapies to patients,” says Martin Olovsson, CEO at OnDosis.

Photo of Martin Olovsson: OnDosis